Although a higher rate of pCR in HER2 IHC 3+ tumours was reported in the Krystel–Whittemore study [9], their cohort had higher proportions of histological grade 3, ER negative and patients who received dual anti-HER2 therapy. This evidence concerns the gene ERBB2 and neoplasm.